Evolent's 25% 2027 Revenue Bet Looks Real-If 2027 EBITDA Holds at $150M

Management paired its 2027 outlook with current results

Evolent made its 2027 case harder to dismiss by releasing its 2027 outlook on the same day as its second quarter 2026 financial results. Management said it expects revenue growth of over 25% compared to 2026 and that the midpoint of its 2027 Adjusted EBITDA outlook will be at or above $150 million. Because the forward view came alongside current financials, investors can judge it against real operating numbers instead of treating it as a standalone narrative.

What has to prove out

Management tied the outlook to contracts in place today, upcoming launches, and continued demand for its oncology solution. If that foundation holds, investors can start underwriting 2027 earnings power before the broader market fully prices it in.

The main risk is execution. Recent claim and pricing pressure already showed up in the 93.3% MER. One soft quarter does not break the story, but another would make the 2027 targets much harder to defend.

Why the 25% growth target is not just optimism

Evolent's 2027 case looks more credible because it comes from a platform with breadth, not from a single niche product carrying the whole thesis.

Growth is coming through a broader suite

Evolent's solution map spans oncology, cardiology, musculoskeletal care, primary care, administrative services, advanced illness, genetic testing, physical medicine, radiology, and surgical management. That breadth can support deeper client relationships and make growth less dependent on any one win.

Recent operating data adds context. Q1 2026 revenue was $496.2 million, up 2.6% year over year, and that growth was tied to new Performance Suite contracts and commercial momentum. Performance Suite revenue reached $323.3 million, suggesting product-led revenue is becoming more important to the business.

What makes the next jump more plausible

Management's 2027 case rests on three concrete inputs: contracts in place today, upcoming launches scheduled, and strong continuing demand for our oncology solution. First-quarter commentary also pointed to successful launches with Aetna and Highmark and expansion in oncology and AI, which suggests the company already has active expansion paths into named accounts.

There is also a discipline angle. Management said it is confident in its emerging AI-led operational model and highlighted expense reductions as a lever for 2027. That matters because the key question is not just whether revenue can grow, but whether larger revenue can still support stronger earnings.

The real test is whether margins improve in 2027

The growth story only works if the margin profile improves from where it is now.

The margin bridge is tight

A 25%+ revenue increase from 2026 would put 2027 revenue firmly above recent levels. Hitting a $150 million EBITDA midpoint from there still leaves room for improvement, but not much room for another round of margin slippage.

Recent results show why that matters. In Q1, Adjusted EBITDA margin was 4.4%, down from 7.6% a year earlier. The more immediate pressure point was pricing and claims behavior: the MER excluding ECP was 93.3%, up from 84.0%. Management's second-quarter commentary also pointed to margin pressure, citing significant continued industry headwinds from Medicaid and other client specific membership attrition alongside expected margin improvement and expense discipline.

What investors should watch next

The clearest signal to watch is whether the next few quarters show better claim behavior and better conversion of revenue into earnings. Management has pointed to improvement in Performance Suite care margins, expense reductions, and its AI-led operating model, but that still needs to show up consistently in reported results.